Neuronal nicotinic acetylcholine receptor subunit alpha-4 (CHRNA4)

Neuronal nicotinic acetylcholine receptor subunit alpha-4 (CHRNA4) is a critical component of the most abundant high-affinity nicotinic receptors in the human central nervous system, typically forming heteropentameric complexes with beta-2 subunits (UniProt P43681). These receptors function as ligand-gated cation channels that mediate fast excitatory neurotransmission and modulate the release of key neurotransmitters such as dopamine and glutamate (PubMed: 39193833). CHRNA4 plays a central role in cognitive processes, including attention, memory, and reward pathways, making it a primary therapeutic target for nicotine dependence and smoking cessation (MedlinePlus Genetics). Clinically, pathogenic variants in the CHRNA4 gene are a known cause of autosomal dominant sleep-related hypermotor epilepsy, where hypersensitivity of the receptor leads to nocturnal seizures (PubMed: 7550350). Beyond epilepsy and addiction, the subunit is increasingly investigated for its role in neurodegenerative diseases like Alzheimer's and Parkinson's, where cholinergic signaling is often compromised (PubMed: 39193833). Drugs interacting with this target, such as varenicline, leverage partial agonism to balance receptor activation and desensitization, though they require monitoring for neuropsychiatric side effects (PubChem CID 5310966).

Other names

Acetylcholine receptor subunit alpha-4nAChR subunit alpha-4Cholinergic receptor nicotinic alpha 4 subunitNACHRA4NACRA4BFNCEBN1

Drugs targeting this subunit typically act as agonists or partial agonists that bind to the extracellular interface of the alpha-4 and beta-2 subunits, inducing a conformational change that opens the central ion-conducting pore. This allows the influx of sodium and calcium ions, leading to neuronal depolarization and the subsequent release of various neurotransmitters, including dopamine, GABA, and glutamate (UniProt P43681, PubMed: 17303215). Positive allosteric modulators like NS9283 enhance the receptor's response to acetylcholine without binding to the orthosteric site (PubMed: 22013211).